RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dongkook Pharmaceutical Co Stock

Dongkook Pharmaceutical Co ROA 2024

Dongkook Pharmaceutical Co ROA

0.06

Ticker

086450.KQ

ISIN

KR7086450004

In 2024, Dongkook Pharmaceutical Co's return on assets (ROA) was 0.06, a -18.38% increase from the 0.07 ROA in the previous year.

Dongkook Pharmaceutical Co Aktienanalyse

What does Dongkook Pharmaceutical Co do?

Dongkook Pharmaceutical Co Ltd is a South Korean company that specializes in the development and manufacturing of pharmaceutical products. It was founded in 1968 by Choon-kyu Kim, who was working in the research department of Pfizer at the time and wanted to start his own company. During the early years, Dongkook focused on the formulation of drugs and medications manufactured by other companies. In the 1980s, Dongkook expanded its business and started developing and manufacturing its own products. A new facility was also built in Bucheon, a suburb of Seoul, during this time. Production focused on prescription medications, particularly cardiovascular drugs and antidiabetic agents. Dongkook became one of the leading companies in South Korea in this area. In the 1990s, Dongkook continued its expansion and began focusing on the Asian market. New markets were tapped into and partnerships with other pharmaceutical companies were established. In 2000, Dongkook went public, providing additional capital. Today, Dongkook is a globally operating company with a wide portfolio of medications and healthcare products. The company is divided into various business segments, including cardiovascular, diabetes, gastrointestinal, and dermatology. Each of these segments encompasses a wide range of products, from prescription drugs to over-the-counter dietary supplements. In the cardiovascular segment, Dongkook offers pharmaceuticals for the treatment of conditions such as heart failure, hypertension, and angina pectoris. The diabetes segment includes medications for the treatment of type 2 diabetes and other metabolic disorders. In the gastrointestinal segment, Dongkook produces medications for the treatment of stomach and intestinal problems, as well as for supporting the digestive system. In dermatology, the company manufactures medications for the treatment of skin diseases and cosmetic products. An important focus of Dongkook is the research and development of new innovative products. The company has its own research and development department, where work is done on new medications and technologies. Through close collaboration with other companies and research institutions around the world, Dongkook has been able to develop numerous products that are distinguished by their high quality and effectiveness. Dongkook is also committed to promoting sustainable and environmentally friendly business practices. The company is dedicated to the use of renewable energies and continuously works on measures to reduce its environmental impact. Additionally, the company is an active member of the community and supports numerous social initiatives, such as donation campaigns for non-profit organizations, educational programs, and environmental conservation projects. In summary, Dongkook Pharmaceutical Co Ltd is a leading global pharmaceutical company known for its innovation, product quality, and sustainable business practices. With a wide portfolio of medications and healthcare products, as well as a strong research and development department, the company is well-positioned for the future and will continue to play an important role in the pharmaceutical industry. Dongkook Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Dongkook Pharmaceutical Co's Return on Assets (ROA)

Dongkook Pharmaceutical Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Dongkook Pharmaceutical Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Dongkook Pharmaceutical Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Dongkook Pharmaceutical Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Dongkook Pharmaceutical Co stock

What is the Return on Assets (ROA) of Dongkook Pharmaceutical Co this year?

The Return on Assets (ROA) of Dongkook Pharmaceutical Co is 0.06 undefined this year.

What was the ROA of Dongkook Pharmaceutical Co compared to the previous year?

The ROA of Dongkook Pharmaceutical Co has increased by -18.38% compared to the previous year.

What consequences do high ROA have for investors of Dongkook Pharmaceutical Co?

A high ROA is advantageous for investors of Dongkook Pharmaceutical Co, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Dongkook Pharmaceutical Co?

A low ROA can be unfavorable for investors of Dongkook Pharmaceutical Co as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Dongkook Pharmaceutical Co affect the company?

An increase in ROA of Dongkook Pharmaceutical Co can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Dongkook Pharmaceutical Co impact the company?

A reduction in the ROA of Dongkook Pharmaceutical Co can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Dongkook Pharmaceutical Co?

Some factors that can influence the ROA of Dongkook Pharmaceutical Co include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Dongkook Pharmaceutical Co important for investors?

The ROA of Dongkook Pharmaceutical Co is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Dongkook Pharmaceutical Co take to improve ROA?

To improve ROA, Dongkook Pharmaceutical Co can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Dongkook Pharmaceutical Co pay?

Over the past 12 months, Dongkook Pharmaceutical Co paid a dividend of 180 KRW . This corresponds to a dividend yield of about 1.07 %. For the coming 12 months, Dongkook Pharmaceutical Co is expected to pay a dividend of 196.06 KRW.

What is the dividend yield of Dongkook Pharmaceutical Co?

The current dividend yield of Dongkook Pharmaceutical Co is 1.07 %.

When does Dongkook Pharmaceutical Co pay dividends?

Dongkook Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of Dongkook Pharmaceutical Co?

Dongkook Pharmaceutical Co paid dividends every year for the past 15 years.

What is the dividend of Dongkook Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 196.06 KRW are expected. This corresponds to a dividend yield of 1.16 %.

In which sector is Dongkook Pharmaceutical Co located?

Dongkook Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dongkook Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dongkook Pharmaceutical Co from 4/19/2024 amounting to 180 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did Dongkook Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 4/19/2024.

What was the dividend of Dongkook Pharmaceutical Co in the year 2023?

In the year 2023, Dongkook Pharmaceutical Co distributed 180 KRW as dividends.

In which currency does Dongkook Pharmaceutical Co pay out the dividend?

The dividends of Dongkook Pharmaceutical Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Dongkook Pharmaceutical Co

Our stock analysis for Dongkook Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dongkook Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.